Advertisement

Abstract

Genital herpes is caused by the herpes simplex virus type 1 or 2 and is regarded as one of the most common sexually transmitted infections (STI) and the main cause of genital ulcer disease (GUD) in the developing world. Antiviral treatment with nucleoside analogues offers clinical benefit to symptomatic individuals with first-episode or primary genital herpes as well as for recurrent herpetic episodes.

Keywords

Genital herpes Genital ulcer disease Sexually transmitted infection Neonatal herpes simplex infection Antiherpetic therapy Treatment guidelines for STI 

References

  1. Brown ZA, Selke S, Zeh J, et al. Acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509–15.CrossRefGoogle Scholar
  2. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427–39.CrossRefGoogle Scholar
  3. Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med. 2009;361:1376–85.CrossRefGoogle Scholar
  4. Corey L, Wald A, Patel R, et al. Once daily Valaciclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11–20.CrossRefGoogle Scholar
  5. Fleming D, McQuillan G, Johnson R, et al. Herpes simplex virus type 2 in the United States. 1976 to 1994. N Engl J Med. 1997;337:1105–11.CrossRefGoogle Scholar
  6. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004;190:1374–81.CrossRefGoogle Scholar
  7. Loveless M, Harris W, Sacks S. Treatment of first episode genital herpes with famciclovir. In: Programms and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995, San Francisco, 1995.Google Scholar
  8. Department of health and human services center for disease control and prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 2010;59(RR-12):20–5.Google Scholar
  9. Safarin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med. 1991;325:551–5.CrossRefGoogle Scholar
  10. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis. 2002;186:1718–25.CrossRefGoogle Scholar
  11. Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305:1441–9.CrossRefGoogle Scholar
  12. Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, et al. Helicase –primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370:201–10.CrossRefGoogle Scholar
  13. Wals A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis. 2006;33:529–33.CrossRefGoogle Scholar
  14. Whitley RJ, Prichard M. A novel potential therapy for HSV. N Engl J Med. 2014;370:273–4.CrossRefGoogle Scholar

Further Reading

  1. Benedetti JK, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121:847–54.CrossRefGoogle Scholar
  2. Bryson YJ, Dillon M, Bernstein DI, Radolf J, Zakowsi P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis. 1993;167:942–6.CrossRefGoogle Scholar
  3. Cowan FM, Copas A, Johnson AM, Ashley R, Corey L, Mindel A. Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence? Sex Transm Infect. 2002;78:346–8.CrossRefGoogle Scholar
  4. Coyle PV, O’Neill HJ, Wyatt DE, McCaughey C, Quash S, McBride MQ. Emergence of herpes simplex type 1 as the main cause of recurrent genital ulcerative disease in women in Northern Ireland. J Clin Virol. 2003;27:22–9.CrossRefGoogle Scholar
  5. Crumpacker CS, Schnipper LE, Marlowe ST, Kowalsky PN, Hershey BJ, Levin MJ. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982;306:343–6.CrossRefGoogle Scholar
  6. Dillon SM, Cummings SM, Rajagopalan S, Mc Cormack WC. Prospective analysis of genital ulcer disease in Brooklyn, New York. Clin Infect Dis. 1997;24:945–50.CrossRefGoogle Scholar
  7. Five KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. The Acyclovir Study Group. Recurrence and resistance pattern of herpes simplex virus following cessation of >6 years of chronic suppression with acyclovir. J Infect Dis. 1994;169:1338–41.CrossRefGoogle Scholar
  8. Johnson LS, Nahmias AJ, Magder RE, et al. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med. 1989;321:7–12.CrossRefGoogle Scholar
  9. Lafferty WE, Downey L, Celum C, Wals A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis. 2000;181:1454–7.CrossRefGoogle Scholar
  10. Mertz GJ. Epidemiology of genital herpes infections. Infect Dis Clin North Am. 1993;7:825–39.PubMedGoogle Scholar
  11. Mitchell PS, Espy MJ, Smith TF, Toal DR, Rys PN, Berbari EF, Osmon DR, Persing DH. Laboratory diagnosis of central nervous system infections with herpes simples virus by PCR performed with cerebrospinal fluid specimens. J Clin Microbiol. 1997;35:2873–7.PubMedPubMedCentralGoogle Scholar
  12. Patel R, Alderson S, Geretti A, et al. European guideline for the management of genital herpes. 2010. www.lusti.org/regions/europe.
  13. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother. 1993;4:47–55.CrossRefGoogle Scholar
  14. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42:418–27.CrossRefGoogle Scholar
  15. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes. N Engl J Med. 1981;305:315–9.CrossRefGoogle Scholar
  16. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA. 1996;276:44–9.CrossRefGoogle Scholar
  17. Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest. 2001;108:503–10.CrossRefGoogle Scholar
  18. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333:770–5.CrossRefGoogle Scholar
  19. Wald A, Matson P, Ryncarz A, Corey L. Detection of herpes simplex virus DNA in semen of men with genital HSV-2 infection. Sex Transm Dis. 1999;26:1–3.CrossRefGoogle Scholar
  20. Wildy P. Herpes history and classification. In: AS K, editor. The herpes viruses. New York: Academic; 1973. p. 1–25.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Medical Director of the Outpatients Centre for Infectious Venerodermatological Diseases, Centre for STIViennaAustria

Personalised recommendations